Design Therapeutics (DSGN) Revenue (2020)

Design Therapeutics recorded quarterly Revenue of $33000.0 in Q4 2020, up 65.0% quarter-over-quarter from $20000.0 in Q3 2020.

Design Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $33000.0 for Q4 2020.

  • In Q4 2020, Revenue changed N/A year-over-year to $33000.0; the TTM figure through Dec 2020 stood at $226000.0 (changed N/A YoY), while the FY2020 annual figure was $226000.0, changed N/A from the prior year.
  • Revenue came in at $33000.0 for Q4 2020 at Design Therapeutics, up from $20000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $142000.0 in Q1 2020 to a low of $20000.0 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.17 Bn
10 Design Therapeutics 640.15 Mn 417.32 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 33,000.00
Sep 30, 2020 20,000.00
Jun 30, 2020 31,000.00
Mar 31, 2020 142,000.00